Editorial 3rd Intercontinental Cooperative ITP Study Group (ICIS) Expert Meeting in Basel, Switzerland, September 2009 by Kühne, Thomas & Imbach, Paul
EDITORIAL
Editorial 3rd Intercontinental Cooperative ITP
Study Group (ICIS) Expert Meeting in Basel,
Switzerland, September 2009
Thomas Kühne & Paul Imbach
Received: 22 March 2010 /Accepted: 23 April 2010 /Published online: 7 May 2010
# Springer-Verlag 2010
On September 3–5, 2009, the 3rd Intercontinental Coopera-
tive ITP Study Group (ICIS) Expert Meeting was held in
Basel, Switzerland. After Bürgenstock (2003) and Yverdon
(2006), the meeting is gaining a status of tradition. More than
100 experts involved in basic science and clinical researchmet
to discuss consensus issues and development of strategies in
immune thrombocytopenia (ITP). This issue of Annals of
Hematology represents a compilation of lectures and working
group discussions. The four working groups “Basic science”,
“Management endpoints of ITP”, “Chronic ITP”, and “Future
research: resources and regulations” were preceded by
lectures of the same topic. Speakers were invited to send a
review article of their lecture. The articles of Clemetson and
Panzer, Tamary et al., Grainger et al., and Zehnder et al.
represent summaries of the working group discussions, which
were submitted after the meeting and after consensus work of
co-authors and participants.
The ICIS Expert Meeting was a great opportunity to
exchange new knowledge and to plan for the future. “Basic
science” is reflected by the articles of Biburger et al., Pang and
Lazarus, Semple, and Speer and Schmugge. Neunert, and
Klaassen and Young wrote an article evaluating bleeding for
“Management endpoints”, and Godeau and Michel, Bolton-
Maggs and Kok, Kühne and Imbach, Jawa et al. and
Wadenvik and Olsson wrote for the group “Chronic ITP”.
Bergmann et al. wrote an article about genetics in pediatric
ITP for the group “Future research”.
Immune thrombocytopenia, formerly called idiopathic or
immune thrombocytopenic purpura is a bleeding diathesis
with the hallmark of thrombocytopenia, resulting from
premature platelet destruction by the monocytic–phagocytic
system and by certain degree of platelet production failure.
In a majority of patients, autoantibodies of various
specificities can be detected, however, not in every patient,
which indicates heterogeneity of the etiology and immune
pathophysiology in patients with ITP. It is this heterogene-
ity which may be responsible for different degrees of
responses to therapeutic interventions, and also for the
many debates and controversies around ITP. The terminol-
ogy, definitions, and the practice guidelines characterizing
ITP have recently been improved by the international
harmonization report [1] and by the international consensus
report [2]. However, there are many open questions which
have been addressed by ICIS since more than 12 years.
ICIS was founded by several hematologists to establish a
network of scientists and physicians involved in the field of
ITP. Several registries have been developed, of which two
are closed and published (Registry I 1997–2000 with 2,786
patients and Registry II 2002–2004 with 1,388 patients).
Please visit www.itpbasel.ch for references. Currently, there
are two registries open: the Pediatric and Adult Registry on
Chronic ITP since 2004 with 2,040 patients and the
Splenectomy Registry (since 1998 with 174 patients).
Within the 12-year experience of ICIS registries, we learned
how to formulate registry questions, electronic data
management including online processes, and data quality
assessments. Data control and evaluation need cautiousness
and high professional experience. Scientific results and
publications have to be peer-reviewed by experts of
registries. Ongoing communication and discussion through
regular international meetings support this process.
Attending experts, speakers, and manuscript authors did
a great job and made our meeting a fruitful and successful
event. Our thanks go to all active participants of the
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meeting and to all ICIS investigators. Warm thanks go to
Verena Stahel, Caroline Martin, and Monika Imbach, our
ICIS office staff, as well as to Erika Scheibli, secretary, who
are all wonderful organizers. The research activities of ICIS
are supported by the ITP Foundation founded by family
McGuire, the Eduard Waeffler–Ludwig Stiftung Basel
Fund, and the University Children’s Hospital Basel, as well
as industrial support by Amgen, Biotest, CSL Behring, F.
Hoffmann–La Roche, GlaxoSmithKline, and PPTA.
ITP reflects since its description by Paul Gottlieb
Werlhof a fast-changing field. It becomes clearer that it is
not a disorder, not Werlhof’s disease, but rather an
immunological phenomenon caused by different factors
and mechanisms. We hope that such ICIS meetings
stimulate the participants and all participating and interested
investigators to maintain their enthusiasm and energy to
further develop basic and clinical research which ultimately
will help children and adults with ITP. All meeting
participants and ICIS investigators can be seen by visiting
our homepage www.itpbasel.ch.
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